Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The development of an effective TB vaccine remains paramount to achieving the goal of global eradication of TB by 2050. The only licensed vaccine, BCG, has variable efficacy and is poorly effective in high burden countries. The development of promising candidate vaccines to either 'boost' a BCG primed immune system or replace BCG altogether is a key area for innovative research. Here, we discuss some of the issues encountered in the development of potential candidate vaccines and the future challenges.

Original publication

DOI

10.1136/thoraxjnl-2014-205202

Type

Journal article

Journal

Thorax

Publication Date

03/2015

Volume

70

Pages

299 - 301

Keywords

Tuberculosis, Drug Design, Humans, Mycobacterium tuberculosis, Tuberculosis Vaccines, Tuberculosis, Pulmonary